Journey Medical (DERM) Competitors

$6.19 -0.39 (-5.93%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$6.18 -0.01 (-0.16%)

As of 07/24/2026 07:34 PM Eastern

DERM vs. FBIO, ACRS, DSGN, DRUG, and ZVRA

Should you buy Journey Medical stock or one of its competitors? MarketBeat compares Journey Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Journey Medical include Fortress Biotech (FBIO), Aclaris Therapeutics (ACRS), Design Therapeutics (DSGN), Bright Minds Biosciences (DRUG), and Zevra Therapeutics (ZVRA). These companies are all part of the "medical" sector.

How does Journey Medical compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 408.98%. Journey Medical has a consensus price target of $13.00, indicating a potential upside of 110.02%. Given Fortress Biotech's higher probable upside, equities research analysts plainly believe Fortress Biotech is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Fortress Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.75	$6.82M	$3.17	1.05
Journey Medical	$61.86M	2.75	-$11.43M	-$0.37	N/A

Fortress Biotech has a net margin of 193.12% compared to Journey Medical's net margin of -14.82%. Fortress Biotech's return on equity of 109.66% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Journey Medical	-14.82%	-35.57%	-10.88%

In the previous week, Fortress Biotech had 4 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Fortress Biotech and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.89 beat Fortress Biotech's score of 0.99 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Positive
Journey Medical	Very Positive

Summary

Fortress Biotech beats Journey Medical on 12 of the 14 factors compared between the two stocks.

How does Journey Medical compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Journey Medical has a net margin of -14.82% compared to Aclaris Therapeutics' net margin of -832.58%. Journey Medical's return on equity of -35.57% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Journey Medical	-14.82%	-35.57%	-10.88%

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Aclaris Therapeutics had 4 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Aclaris Therapeutics and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.89 beat Aclaris Therapeutics' score of 1.02 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Aclaris Therapeutics	Positive
Journey Medical	Very Positive

Aclaris Therapeutics presently has a consensus price target of $11.50, indicating a potential upside of 119.89%. Journey Medical has a consensus price target of $13.00, indicating a potential upside of 110.02%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aclaris Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Journey Medical has higher revenue and earnings than Aclaris Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	93.29	-$64.92M	-$0.56	N/A
Journey Medical	$61.86M	2.75	-$11.43M	-$0.37	N/A

Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Summary

Journey Medical beats Aclaris Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Journey Medical compare to Design Therapeutics?

Journey Medical (NASDAQ:DERM) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Design Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Design Therapeutics' return on equity of -33.07% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-14.82%	-35.57%	-10.88%
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Design Therapeutics had 1 more articles in the media than Journey Medical. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.89 beat Design Therapeutics' score of 0.97 indicating that Journey Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Journey Medical	Very Positive
Design Therapeutics	Positive

Journey Medical has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Journey Medical currently has a consensus target price of $13.00, indicating a potential upside of 110.02%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 40.07%. Given Journey Medical's higher probable upside, research analysts plainly believe Journey Medical is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Journey Medical has higher revenue and earnings than Design Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.75	-$11.43M	-$0.37	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Design Therapeutics beats Journey Medical on 10 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Bright Minds Biosciences has a beta of -5.34, indicating that its stock price is 634% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Bright Minds Biosciences has higher earnings, but lower revenue than Journey Medical. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
Journey Medical	$61.86M	2.75	-$11.43M	-$0.37	N/A

Bright Minds Biosciences presently has a consensus price target of $143.83, indicating a potential upside of 101.64%. Journey Medical has a consensus price target of $13.00, indicating a potential upside of 110.02%. Given Journey Medical's higher probable upside, analysts clearly believe Journey Medical is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Bright Minds Biosciences had 4 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Bright Minds Biosciences and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.89 beat Bright Minds Biosciences' score of 1.31 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Bright Minds Biosciences	Positive
Journey Medical	Very Positive

Bright Minds Biosciences has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Bright Minds Biosciences' return on equity of -20.58% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
Journey Medical	-14.82%	-35.57%	-10.88%

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Bright Minds Biosciences beats Journey Medical on 9 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Zevra Therapeutics has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$122.29M	4.60	$83.23M	$1.99	4.78
Journey Medical	$61.86M	2.75	-$11.43M	-$0.37	N/A

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zevra Therapeutics had 11 more articles in the media than Journey Medical. MarketBeat recorded 12 mentions for Zevra Therapeutics and 1 mentions for Journey Medical. Journey Medical's average media sentiment score of 1.89 beat Zevra Therapeutics' score of 0.45 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Zevra Therapeutics	Neutral
Journey Medical	Very Positive

Zevra Therapeutics currently has a consensus target price of $29.29, indicating a potential upside of 207.62%. Journey Medical has a consensus target price of $13.00, indicating a potential upside of 110.02%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Zevra Therapeutics has a net margin of 101.58% compared to Journey Medical's net margin of -14.82%. Zevra Therapeutics' return on equity of 51.49% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Journey Medical	-14.82%	-35.57%	-10.88%

Zevra Therapeutics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

Summary

Zevra Therapeutics beats Journey Medical on 13 of the 16 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DERM vs. The Competition

Export

Metric	Journey Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$181.18M	$3.08B	$6.87B	$12.26B
Dividend Yield	N/A	2.07%	2.67%	9.79%
P/E Ratio	-16.73	20.29	27.11	23.64
Price / Sales	2.75	485.19	517.09	89.57
Price / Cash	N/A	27.62	50.54	59.64
Price / Book	6.45	4.13	10.28	6.07
Net Income	-$11.43M	$65.94M	$3.60B	$331.99M
7 Day Performance	-13.55%	-4.16%	-1.27%	-0.63%
1 Month Performance	-0.48%	-3.76%	-0.37%	-2.00%
1 Year Performance	-18.45%	9.94%	18.30%	13.62%

Journey Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DERM Journey Medical	2.5392 of 5 stars	$6.19 -5.9%	$13.00 +110.0%	-19.3%	$181.18M	$61.86M	N/A	90
FBIO Fortress Biotech	2.9513 of 5 stars	$3.53 +6.0%	$17.00 +381.6%	+72.2%	$110.62M	$63.26M	1.11	170	News Coverage
ACRS Aclaris Therapeutics	2.9877 of 5 stars	$5.69 +2.2%	$11.50 +102.1%	+211.3%	$777.93M	$7.83M	N/A	100	News Coverage Positive News
DSGN Design Therapeutics	2.4902 of 5 stars	$12.06 +1.6%	$16.50 +36.8%	+191.6%	$741.36M	N/A	N/A	40
DRUG Bright Minds Biosciences	3.1229 of 5 stars	$77.29 +3.6%	$143.83 +86.1%	+123.0%	$726.12M	N/A	N/A	N/A	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Journey Medical (DERM) Competitors

DERM vs. FBIO, ACRS, DSGN, DRUG, and ZVRA

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to Aclaris Therapeutics?

Summary

How does Journey Medical compare to Design Therapeutics?

Summary

How does Journey Medical compare to Bright Minds Biosciences?

Summary

How does Journey Medical compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Journey Medical (DERM) Competitors

DERM vs. FBIO, ACRS, DSGN, DRUG, and ZVRA

How does Journey Medical compare to Fortress Biotech?

Do analysts rate FBIO or DERM?

Do insiders & institutionals believe in FBIO or DERM?

Which has more risk & volatility, FBIO or DERM?

Which has higher valuation & earnings, FBIO or DERM?

Is FBIO or DERM more profitable?

Does the media prefer FBIO or DERM?

Summary

How does Journey Medical compare to Aclaris Therapeutics?

Is ACRS or DERM more profitable?

Do institutionals & insiders have more ownership in ACRS or DERM?

Does the media refer more to ACRS or DERM?

Do analysts rate ACRS or DERM?

Which has better earnings & valuation, ACRS or DERM?

Which has more risk and volatility, ACRS or DERM?

Summary

How does Journey Medical compare to Design Therapeutics?

Is DERM or DSGN more profitable?

Does the media prefer DERM or DSGN?

Which has more risk and volatility, DERM or DSGN?

Do analysts prefer DERM or DSGN?

Which has stronger earnings and valuation, DERM or DSGN?

Do institutionals and insiders believe in DERM or DSGN?

Summary

How does Journey Medical compare to Bright Minds Biosciences?

Which has more volatility & risk, DRUG or DERM?

Which has preferable valuation & earnings, DRUG or DERM?

Do analysts rate DRUG or DERM?

Does the media refer more to DRUG or DERM?

Is DRUG or DERM more profitable?

Do insiders & institutionals have more ownership in DRUG or DERM?

Summary

How does Journey Medical compare to Zevra Therapeutics?

Which has better valuation & earnings, ZVRA or DERM?

Do insiders & institutionals believe in ZVRA or DERM?

Does the media refer more to ZVRA or DERM?

Do analysts prefer ZVRA or DERM?

Is ZVRA or DERM more profitable?

Which has more risk and volatility, ZVRA or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools